Product Images Clopidogrel Bisulfate

This is medication information for Clopidogrel 75mg tablets, containing 30 tablets per bottle. It is a prescription drug, Lot number C202204, and has an expiration date of 05/22/13. The tablets contain 87,875 mg of clopidogrel bisulfate USP, which is equivalent to 75 mg of clopidogrel base. The usual adult dosage can be found in the package insert. It must be stored at a controlled room temperature of 20-25°C (88-77°F). The CPSNDC number is 67046-099-30. The label indicates that it was packaged by Contract Pharmacy Services-PA, located in Warrington, PA.*

This table provides mean and 90% confidence interval values for the effect of co-administered proton pump inhibitors (PPIs) on the area under the curve (AUC) of the active metabolite. The data is presented for four PPIs: Dexlansoprazole (60 mg), Lansoprazole (30 mg), Pantoprazole (80 mg), and Omeprazole (80 mg). The symbols "T T T T" are unclear, and there is no clear contextual information provided to determine their meaning.*

This is a comparison chart of two medications, Placebo (with aspirin) and Clopidogrel (with aspirin), in terms of their cumulative event rate. The chart displays data for months of follow-up and indicates a cumulative event rate of 0.00009. The use of other standard therapies was also considered.*

The text appears to be a summary of a clinical trial comparing the efficacy of a placebo versus Clopidogrel (a blood thinner) in reducing proportional risk of death. The trial resulted in a 7% reduction in risk of death with Clopidogrel compared to the placebo. The data presented indicates the number of deaths recorded for both groups (1845 for placebo and 1726 for Clopidogrel) at different time intervals after randomization.*

This text appears to describe the results of a medical study comparing the effectiveness of a drug called Clopidogrel versus a placebo. The study monitored patients for the occurrence of death, reinfarction, or stroke prior to their first discharge from the hospital. The results show that among patients who took Clopidogrel, there was a 9% lower risk of experiencing these negative outcomes compared to those who took the placebo. The study was conducted over a period of up to 28 days.*